{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:55:34Z","timestamp":1792108534669,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The ALLEGRO phase IIa and IIb\/III (NCT02974868 and NCT03732807) studies have demonstrated that ritlecitinib is effective and well tolerated in adults and adolescents with alopecia areata (AA) up to 48 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the efficacy of ritlecitinib through month 24 and safety through data cutoff in the ALLEGRO phase IIb\/III study and the ongoing long-term open-label phase III ALLEGRO-LT study (NCT04006457).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged \u2265 12\u2005years with AA and \u2265 50% scalp hair loss from ALLEGRO IIb\/III who rolled over to ALLEGRO-LT after up to 48 weeks were included. Proportions of patients with responses based on clinician-reported Severity of Alopecia Tool (SALT) scores of \u2264 20 and \u2264 10, eyebrow assessment (EBA) and eyelash assessment (ELA), patient global impression of change (PGI-C) and patient satisfaction with hair growth were reported through month 24 for patients who received ritlecitinib 50\u2005mg daily with or without a 200-mg 4-week daily loading dose. Observed and imputed data [last observation carried forward (LOCF)] were reported up to 9 December 2022. Safety was assessed throughout.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At month 12, a SALT score \u2264 20 was achieved by 45.1% and 45.9% (observed) and 40.3% and 41.8% (LOCF) of the 191 and 194 patients who received ritlecitinib 50\u2005mg and ritlecitinib 200\u2005mg\/50\u2005mg, respectively. At month 24, these proportions increased to 60.8% and 63.1% (observed) and 46.1% and 50.8% (LOCF), respectively. Patients with abnormal EBA or ELA scores at baseline achieved responses at month 24 [EBA observed: 57.6% (50\u2005mg), 61.0% (200\/50\u2005mg); EBA LOCF: 46.8% (50\u2005mg), 50.9% (200\/50\u2005mg); ELA observed: 51.2% (50\u2005mg), 62.7% (200\/50\u2005mg); ELA LOCF: 43.2% (50\u2005mg), 51.7% (200\/50\u2005mg)]. PGI-C response was achieved by patients at month 24 [observed: 70.0% (50\u2005mg), 76.4% (200\/50\u2005mg); LOCF: 56.6% (50\u2005mg), 65.5% (200\/50\u2005mg)]. Safety profiles for both treatment groups were consistent with the known safety profile of ritlecitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ritlecitinib has clinically meaningful and sustained efficacy beyond 1\u2005year with a favourable safety and tolerability profile, supporting its long-term use in patients aged \u2265 12\u2005years with AA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae365","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:24:19Z","timestamp":1729265059000},"page":"215-227","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata"],"prefix":"10.1093","volume":"192","author":[{"given":"Melissa","family":"Piliang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"Southern California Dermatology , Santa Ana, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"additional","affiliation":[{"name":"Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"New York University School of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[{"name":"Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Farrant","sequence":"additional","affiliation":[{"name":"Dermatology Department, University Hospitals Sussex NHS Foundation Trust , Brighton ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[{"name":"University Hospital M\u00fcnster , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences, University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Groton, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Woodworth","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville , PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2025090106570488300_ljae365-B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025090106570488300_ljae365-B2","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025090106570488300_ljae365-B3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025090106570488300_ljae365-B4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"2025090106570488300_ljae365-B5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025090106570488300_ljae365-B6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025090106570488300_ljae365-B7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025090106570488300_ljae365-B8","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2025090106570488300_ljae365-B9","doi-asserted-by":"crossref","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"2025090106570488300_ljae365-B10","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"2025090106570488300_ljae365-B11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025090106570488300_ljae365-B12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025090106570488300_ljae365-B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1 Suppl.","key":"2025090106570488300_ljae365-B14","first-page":"s12","article-title":"The biology, structure, and function of eyebrow hair","volume":"13","author":"Nguyen","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2025090106570488300_ljae365-B15","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s13555-023-01044-5","article-title":"Treatments for moderate-to-severe alopecia areata: a systematic narrative review","volume":"13","author":"Egeberg","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025090106570488300_ljae365-B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","article-title":"Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options","volume":"10","author":"Darwin","year":"2018","journal-title":"Int J Trichology"},{"key":"2025090106570488300_ljae365-B17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.36849\/JDD.SF396143","article-title":"Alopecia areata: the clinician and patient voice","volume":"22","author":"Tosti","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"2025090106570488300_ljae365-B18","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1007\/s12325-022-02338-4","article-title":"Treatment patterns and treatment satisfaction among adults with alopecia areata in the United States","volume":"39","author":"Fridman","year":"2022","journal-title":"Adv Ther"},{"key":"2025090106570488300_ljae365-B19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025090106570488300_ljae365-B20","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jisp.2020.04.006","article-title":"Eyebrows are important in the treatment of alopecia areata","volume":"20","author":"Liu","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025090106570488300_ljae365-B21","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jid.2022.02.019","article-title":"Predictors of QOL in patients with alopecia areata","volume":"142","author":"Senna","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025090106570488300_ljae365-B22","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","article-title":"Burden of illness in alopecia areata: a cross-sectional online survey study","volume":"20","author":"Mesinkovska","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"2025090106570488300_ljae365-B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae365\/60961757\/ljae365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/2\/215\/60961757\/ljae365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/2\/215\/60961757\/ljae365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:57:17Z","timestamp":1756724237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/2\/215\/7829168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,21]]},"published-print":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae365","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,21]]}}}